Trial Profile
Efficacy and safety of Canakinumab treatment in patients with Adult-Onset Still's disease : a retrospective, multicenter study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Nov 2018
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Adult-onset Still's disease
- Focus Adverse reactions; Therapeutic Use
- 24 Oct 2018 Results assessing efficacy and safety of Canakinumab treatment in Adult-Onset Still's disease, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 13 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism